While some tumor markers are readily available and commonly used clinically, others are not routinely tested due to poor sensitivity and/or specificity. Others are currently under investigation and continue to be evaluated in clinical trials. As research continues, and many areas continue to deepen, it is likely that more effective tumor markers will become available in the coming years, replacing older, less effective markers.

Patients with cancer often have a high risk of death, due to the fact that patients come too late for examination and treatment. Therefore, early cancer screening and screening play a very important role in reducing the risk of death for patients with these cancers.